Key Highlights
- Amgen revealed a new $300 million capital commitment to enhance its biologics production site in Juncos, Puerto Rico.
- The Puerto Rico plant supplies therapeutic products to over 60 nations globally and will undergo significant capacity upgrades.
- This investment builds on more than $650 million previously pledged to Puerto Rico within the last twelve months.
- Across the United States, Amgen has committed upwards of $3.65 billion in manufacturing infrastructure over the past year, spanning Puerto Rico, Ohio, California, and North Carolina.
- The announcement follows President Trump’s executive directive warning of 100% tariffs on imported branded pharmaceuticals.
Amgen (AMGN) shares declined 1.54% during Monday trading following the biotechnology company’s disclosure of an additional $300 million capital injection into its Juncos, Puerto Rico biologics production center.
The capital infusion targets enhanced manufacturing throughput and the implementation of cutting-edge production technologies at the decades-old facility, which has served as a critical manufacturing hub since its establishment in 1992.
Currently, the Juncos complex serves as a distribution point for biologic therapies reaching more than 60 international markets. The planned expansion will bolster the existing workforce while generating hundreds of temporary construction positions.
Chief Executive Officer Robert Bradway characterized the expansion as evidence of Amgen’s “ongoing dedication to U.S.-based manufacturing” and emphasized its role in securing domestic pharmaceutical supply channels and ensuring uninterrupted patient medication access.
Puerto Rico’s Governor Jenniffer González Colón praised the development, stating the commitment validates that her administration’s policies fostering the territory’s biopharmaceutical industry are yielding results.
The $300 million allocation supplements the $650 million Amgen previously earmarked for Puerto Rico operations during the preceding twelve months, which was projected to generate approximately 750 employment opportunities.
Broader Domestic Manufacturing Strategy
This recent pledge represents one component of a comprehensive national investment initiative. Throughout the previous year, Amgen disclosed $900 million designated for Ohio facilities, $600 million allocated toward a California-based science and innovation hub, and over $1.5 billion committed to North Carolina operations.
When combined with the newly announced Puerto Rico investment, Amgen’s recent United States manufacturing allocations surpass $3.65 billion in total value.
Since the 2017 passage of the Tax Cuts and Jobs Act, Amgen reports having deployed over $40 billion toward manufacturing infrastructure and research initiatives.
Tariff Pressures Influencing Industry Strategy
The investment announcement arrives as international pharmaceutical manufacturers confront escalating scrutiny from the Trump administration regarding drug imports.
In April, President Trump executed an executive order establishing 100% tariff rates on branded pharmaceutical products entering United States markets, unless producers accepted government-negotiated pricing structures or committed to domestic manufacturing operations.
Amgen’s broadened domestic manufacturing presence strategically positions the organization to address these regulatory challenges, though company representatives characterized the Puerto Rico enhancement as an element of a broader, long-term supply chain optimization plan.
As a United States territory, Puerto Rico has functioned as a pharmaceutical manufacturing center for more than six decades and currently houses numerous major pharmaceutical corporation facilities.
The Juncos location has been integrated into Amgen’s production network since 1992 and serves a pivotal function in the company’s worldwide biologics distribution infrastructure.
Amgen has yet to disclose a definitive completion schedule for the most recent Puerto Rico expansion project.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
